SOP Guide for Pharma

SOP for Study Design Planning

Protocol for Planning BA/BE Studies

Purpose

The purpose of this Standard Operating Procedure (SOP) is to outline the process for planning the design of Bioavailability (BA) and Bioequivalence (BE) studies in the pharmaceutical industry.

Scope

This SOP applies to all personnel involved in the planning, conduct, and oversight of BA and BE studies, including Principal Investigators, Study Directors, and Regulatory Affairs personnel.

Responsibilities

Procedure

  1. Define the objectives of the BA/BE study, including the specific drugs or formulations to be compared and the parameters to be measured.
  2. Conduct a thorough review of relevant literature, regulatory guidelines, and previous studies to inform study design decisions.
  3. Select an appropriate study design, considering factors such as study population, dosing regimen, sample size, and statistical methods.
  4. Develop a detailed study protocol outlining all aspects of the study design, including inclusion and exclusion criteria, study endpoints, sample collection procedures, and data analysis plan.
  5. Obtain necessary approvals from regulatory authorities and ethics committees before proceeding with the study.
  6. Conduct a pre-study meeting with all study personnel to review the protocol, clarify roles and responsibilities, and address any questions or concerns.
  7. Implement any necessary amendments to the protocol based on feedback from regulatory authorities or study team members.
  8. Finalize the study design and protocol, ensuring that all stakeholders are in agreement and that the study is ready to proceed.

Abbreviations

Documents

Reference

Regulatory guidelines relevant to the specific type of BA/BE study being conducted.

SOP Version

Version 1.0

Exit mobile version